In the wake of the 2022 overturn of Roe v. Wade, a U.S. Supreme Court decision temporarily upholds the FDA's approval of the abortion pill, Mifepristone, which allows clinicians to prescribe it via telehealth and patients to receive it via mail order. Advocates for reproductive rights were quick to celebrate, despite a lawsuit filed by opponents still making its way through the lower courts.